Drug Trial Radar · NCT04638543
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Nov 27, 2020
Primary completion
Oct 26, 2021
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics study of 6 different dose regimens of ABP-671 compared with placebo. The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing. Each dose group will have 3 stages following screening: Run-in, Dose Evaluation, and Follow-up.
Conditions
- Gout
- Hyperuricemia
Interventions
ABP-671Drug
ABP-671 Tablet
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percentage change in serum uric acid (sUA) levelsTime frame: Baseline to the end of the 4-week Dose Evaluation Period
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Paratus - Canberra Clinic
Canberra, Australia
Paratus - Central Coast Clinic
Kanwal, Australia
Peninsula Private Hospital
Kippa-Ring, Australia
Emeritus Research - Melbourne
Melbourne, Australia
Paratus - Western Sydney Clinic
Sydney, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.